AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
184.60
-0.98 (-0.53%)
At close: May 9, 2025, 4:00 PM
184.97
+0.37 (0.20%)
After-hours: May 9, 2025, 7:59 PM EDT
AbbVie Revenue
AbbVie had revenue of $13.34B in the quarter ending March 31, 2025, with 8.39% growth. This brings the company's revenue in the last twelve months to $57.37B, up 5.45% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$57.37B
Revenue Growth
+5.45%
P/S Ratio
5.69
Revenue / Employee
$1,043,036
Employees
55,000
Market Cap
326.55B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
Thermo Fisher Scientific | 42.90B |
ABBV News
- 3 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV - GlobeNewsWire
- 4 days ago - AbbVie to Present at the Bank of America Securities Healthcare Conference - PRNewsWire
- 5 days ago - Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms - CNBC
- 9 days ago - BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - PRNewsWire
- 10 days ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC
- 11 days ago - Best Dividend Aristocrats For May 2025 - Seeking Alpha
- 11 days ago - Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga
- 11 days ago - RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA) - PRNewsWire